Aromatase inhibitors-where are we now?
Open Access
- 1 February 1996
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 73 (4) , 415-417
- https://doi.org/10.1038/bjc.1996.73
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.1995
- Recent advances in biochemical markers of bone turnoverClinical Chemistry, 1994
- Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patientsBreast Cancer Research and Treatment, 1994
- Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancerEuropean Journal Of Cancer, 1994
- The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Aminoglutethimide enzyme induction: pharmacological and endocrinological implicationsCancer Chemotherapy and Pharmacology, 1990
- Aromatase inhibitors in the treatment of advanced breast cancerCancer Treatment Reviews, 1989
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982
- Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.BMJ, 1981
- Diabetes Mellitus Associated with Epidemic of Infectious Hepatitis in NigeriaBMJ, 1974